Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 282989, 13 pages
http://dx.doi.org/10.1155/2012/282989
Review Article

Pharmacokinetic Models for FcRn-Mediated IgG Disposition

Department of Clinical Pharmacology, Genentech Inc., 1 DNA Way, MS 463A, South San Francisco, CA 94080, USA

Received 30 January 2012; Accepted 28 February 2012

Academic Editor: Dobromir Dobrev

Copyright © 2012 Jim J. Xiao. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. W. R. Brambell, W. A. Hemmings, and I. G. Morris, “A theoretical model of γ-globulin catabolism,” Nature, vol. 203, no. 4952, pp. 1352–1355, 1964. View at Publisher · View at Google Scholar · View at Scopus
  2. F. W. Brambell, “The transmission of immunity from mother to young and the catabolism of immunoglobulins.,” The Lancet, vol. 2, no. 7473, pp. 1087–1093, 1966. View at Google Scholar · View at Scopus
  3. T. A. Waldmann and W. Strober, “Metabolism of immunoglobulins,” Progress in Allergy, vol. 13, pp. 1–110, 1969. View at Google Scholar · View at Scopus
  4. R. P. Junghans and C. L. Anderson, “The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 11, pp. 5512–5516, 1996. View at Google Scholar · View at Scopus
  5. J. Borvak, J. Richardson, C. Medesan et al., “Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice,” International Immunology, vol. 10, no. 9, pp. 1289–1298, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. V. Ghetie, J. G. Hubbard, J. K. Kim, M. F. Tsen, Y. Lee, and E. S. Ward, “Abnormally short serum half-lives of IgG in β2-microglobulin-deficient mice,” European Journal of Immunology, vol. 26, no. 3, pp. 690–696, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. R. M. Campbell, D. P. Cuthbertson, C. M. Matthews, and A. S. McFarlane, “Behaviour of 14C- and 131I-labelled plasma proteins in the rat,” The International Journal of Applied Radiation and Isotopes, vol. 1, no. 1-2, pp. 66–84, 1956. View at Google Scholar · View at Scopus
  8. A. S. McFarlane, “The behavior of I 131-labeled plasma proteins in vivo,” Annals of the New York Academy of Sciences, vol. 70, no. 1, pp. 19–25, 1957. View at Google Scholar
  9. T. S. Ramalingam, S. A. Detmer, W. L. Martin, and P. J. Bjorkman, “IgG transcytosis and recycling by FcRn expressed in MDCK cells reveals ligand-induced redistribution,” The EMBO Journal, vol. 21, no. 4, pp. 590–601, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. E. J. Israel, D. F. Wilsker, K. C. Hayes, D. Schoenfeld, and N. E. Simister, “Increased clearance of IgG in mice that lack β2-microglobulin: possible protective role of FcRn,” Immunology, vol. 89, no. 4, pp. 573–578, 1996. View at Google Scholar · View at Scopus
  11. R. D. Wochner, G. Drews, W. Strober, and T. A. Waldmann, “Accelerated breakdown of immunoglobulin G (IgG) in myotonic dystrophy: a hereditary error of immunoglobulin catabolism.,” The Journal of Clinical Investigation, vol. 45, no. 3, pp. 321–329, 1966. View at Google Scholar · View at Scopus
  12. T. A. Waldmann and W. D. Terru, “Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin,” The Journal of Clinical Investigation, vol. 86, no. 6, pp. 2093–2098, 1990. View at Google Scholar · View at Scopus
  13. J. Kim, W. L. Hayton, J. M. Robinson, and C. L. Anderson, “Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model,” Clinical Immunology, vol. 122, no. 2, pp. 146–155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Gurbaxani, “Mathematical modeling as accounting: predicting the fate of serum proteins and therapeutic monoclonal antibodies,” Clinical Immunology, vol. 122, no. 2, pp. 121–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Imbach, S. Barandun, V. d'Apuzzo et al., “High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood,” The Lancet, vol. 1, no. 8232, pp. 1228–1231, 1981. View at Google Scholar
  16. R. Deng and J. P. Balthasar, “Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia,” Journal of Pharmaceutical Sciences, vol. 96, no. 6, pp. 1625–1637, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. Hansen and J. P. Balthasar, “Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura,” Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 1, pp. 165–171, 2001. View at Google Scholar · View at Scopus
  18. F. Jin and J. P. Balthasar, “Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura,” Human Immunology, vol. 66, no. 4, pp. 403–410, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Xiao, W. Krzyzanski, Y. M. Wang et al., “Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys,” AAPS Journal, vol. 12, no. 4, pp. 646–657, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Z. Ferl, A. M. Wu, and J. J. DiStefano, “A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn),” Annals of Biomedical Engineering, vol. 33, no. 11, pp. 1640–1652, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Garg and J. P. Balthasar, “Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 34, no. 5, pp. 687–709, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. R. Urva, V. C. Yang, and J. P. Balthasar, “Physiologically based pharmacokinetic model for T84.66: a monoclonal anti-CEA antibody,” Journal of Pharmaceutical Sciences, vol. 99, no. 3, pp. 1582–1600, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. J. P. Davda, M. Jain, S. K. Batra, P. R. Gwilt, and D. H. Robinson, “A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs,” International Immunopharmacology, vol. 8, no. 3, pp. 401–413, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Hansen and J. P. Balthasar, “Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia,” Journal of Pharmaceutical Sciences, vol. 92, no. 6, pp. 1206–1215, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. R. J. Hansen and J. P. Balthasar, “Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia,” Blood, vol. 100, no. 6, pp. 2087–2093, 2002. View at Google Scholar · View at Scopus
  26. C. R. Hopkins and I. S. Trowbridge, “Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells,” Journal of Cell Biology, vol. 97, no. 2, pp. 508–521, 1983. View at Google Scholar · View at Scopus
  27. R. J. Ober, C. Martinez, C. Vaccaro, J. Zhou, and E. S. Ward, “Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn,” Journal of Immunology, vol. 172, no. 4, pp. 2021–2029, 2004. View at Google Scholar · View at Scopus
  28. W. K. Bleeker, J. L. Teeling, and C. Erik Hack, “Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect,” Blood, vol. 98, no. 10, pp. 3136–3142, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Davies and T. Morris, “Physiological parameters in laboratory animals and humans,” Pharmaceutical Research, vol. 10, no. 7, pp. 1093–1095, 1993. View at Publisher · View at Google Scholar · View at Scopus
  30. S. F. Cure and N. E. Cremer, “Decreased rate of synthesis of immunoglobulin (IgG) in rats infected with moloney leukemia virus.,” Journal of Immunology, vol. 102, no. 6, pp. 1345–1353, 1969. View at Google Scholar · View at Scopus
  31. V. Ghetie, S. Popov, J. Borvak et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nature Biotechnology, vol. 15, no. 7, pp. 637–640, 1997. View at Google Scholar · View at Scopus
  32. P. R. Hinton, M. G. Johlfs, J. M. Xiong et al., “Engineered human IgG antibodies with longer serum half-lives in primates,” The Journal of Biological Chemistry, vol. 279, no. 8, pp. 6213–6216, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Gurbaxani, L. L. Dela Cruz, K. Chintalacharuvu, and S. L. Morrison, “Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life,” Molecular Immunology, vol. 43, no. 9, pp. 1462–1473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. R. P. Junghans, “IgG biosynthesis: no ‘immunoregulatory feedback’,” Blood, vol. 90, no. 10, pp. 3815–3818, 1997. View at Google Scholar · View at Scopus